US VMS Industry Makes Lame Duck Session List, Checks It Twice For MPL Language
Executive Summary
AHPA urges chairs and ranking members of Senate HELP and House Energy and Commerce committees not to pass mandatory product listing legislation or make other changes to FDA regulation of industry before the 117th Congress ends. NPA board members lobby lawmakers about the topic.
You may also be interested in...
US FDA ‘Punt’ On Hemp Rulemaking Frustrates, Confuses Supplement Industry
Industry trade groups say FDA decision against starting rulemaking for lawful use of hemp ingredients is not only overdue but failed to clear the air for businesses making or using the ingredients.
US Budget Stopgap, FDA User Fee Reauthorization On Tap Minus Supplement MPL Program
With current user fee package as well all federal spending programs for FY2022 expiring on 30 September, House and Senate committee leaders reach agreement on FDA user fee reauthorization included in a continuing resolution to extend federal spending at current levels through 16 December.
House Members Object To Senate Adding Supplement MPL Proposal In FDA User Fee Bill
Members led by SC Republican Jeff Duncan and CA Democrat Tony Cárdenas, in letter to House speaker and minority leader, oppose MPL provision in latest version of S.4348 for re-authorizing FDA drug, biologic and medical device user fee programs.